1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Atopic Dermatitis: Update Bulletin #1

Atopic Dermatitis: Update Bulletin #1

  • December 2017
  • ID: 5355968
  • Format: PDF
  • By Firstword Pharma

Summary

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the atopic dermatitis (AD) market, including; Vanda Pharmaceuticals’ announcement of results from an 8-week randomised Phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis; Sanofi and Regeneron’s announcement of positive results from the Phase III CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis who are inadequately controlled with, or intolerant to the broad immunosuppressant drug cyclosporine A (CSA), or when this treatment is medically inadvisable; and AnaptysBio’s announcement of positive proof-of-concept data for ANB020, its investigational anti-IL-33 monoclonal antibody (mAb), in an ongoing Phase IIa clinical trial in adult patients with moderate-to-severe atopic dermatitis.

Business Questions:
• Are KOLs optimistic about tradipitant’s mechanism of action and its potential in the management of chronic pruritus in patients with AD?
• What do KOLs recommend for Phase III studies with tradipitant, and should Vanda Pharmaceuticals include biomarker and gene expression data?
• What impact will tradipitant’s oral formulation have on the product’s attractiveness?
• Are KOLs concerned about the price of tradipitant, and do they believe it can work as a monotherapy?
• Where do KOLs predict that tradipitant will be used in the treatment paradigm; as an adjunctive therapy, as a monotherapy, or in combination with other treatments?
• Do KOLs view the CAFÉ study as a significant step forward, and what impact will it have on the need to use cyclosporine A?
• How do KOLs see the future treatment paradigm of atopic dermatitis evolving as it relates to combination biologic approaches?
• Are KOLs excited about ANB020’s mechanism of action, or does the targeting of IL-33 as a potential treatment strategy for atopic dermatitis have a valid biological rationale?
• What were KOL reactions to the Phase II data for ANB020, and what will KOLs look for from Phase III studies?
• What will be the key drivers of use for ANB020; clinical data, cost or both?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, ...

G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019

G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’G Protein Coupled Bile Acid Receptor 1 - Pipeline Review, H2 2019’; G Protein Coupled ...

Global Organ Transplantation Market: World Market Review By Product Type, By Applications, By Region, By Country (2019 Edition): Forecast to 2024

Global Organ Transplantation Market: World Market Review By Product Type, By Applications, By Region, By Country (2019 Edition): Forecast to 2024

  • $ 2400
  • October 2019

Executive SummaryAccording to the report, the Global Organ Transplantation market is projected to display a robust growth represented by a CAGR of 6.50% during 2019 – 2024.Immunosuppressant drugs hold ...

Warts - Pipeline Review, H2 2019 $ 2000 September 2019


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on